A G Stack1, U Donigiewicz2, A A Abdalla1, A Weiland2, L F Casserly1, C J Cronin1, H T Nguyen2, A Hannigan2. 1. From the Division of Nephrology, Department of Medicine, University Hospital Limerick, Limerick, Graduate Entry Medical School, University of Limerick, Limerick and Department of Medicine, School of Medicine, National University of Ireland, Galway, Ireland From the Division of Nephrology, Department of Medicine, University Hospital Limerick, Limerick, Graduate Entry Medical School, University of Limerick, Limerick and Department of Medicine, School of Medicine, National University of Ireland, Galway, Ireland. 2. From the Division of Nephrology, Department of Medicine, University Hospital Limerick, Limerick, Graduate Entry Medical School, University of Limerick, Limerick and Department of Medicine, School of Medicine, National University of Ireland, Galway, Ireland.
Abstract
BACKGROUND: The contribution of novel risk factors to mortality in chronic kidney disease remains controversial. AIM: To explore the association of plasma fibrinogen with mortality among individuals with normal and reduced kidney function. METHODS: We identified 9184 subjects, age 40 and over from the Third National Health and Nutrition Examination Survey (1988-94) with vital status assessed through 2006. Plasma fibrinogen was modeled as continuous variable and in quartile groups (0 to <7.7, 7.7 to <9.0, 9.0 to <10.5 and ≥ 10.5 µmol/l) with total and cardiovascular mortality across categories of glomerular filtration rate (eGFR); <60, 60-90, >90 ml/min/1.73 m(2) using Cox regression. RESULTS: In multivariate analysis, the adjusted hazard ratio (HR) per 1 µmol/l (34 mg/dl) increase in fibrinogen was 1.07 [95% confidence interval (CI) 1.04-1.09] for total mortality and 1.06 (95% CI 1.03-1.09) for cardiovascular mortality. The adjusted HR for total mortality was 1.05 (1.01-1.09) for subjects with eGFR 60-90 ml/min/1.73 m(2) and 1.06 (1.02-1.10) for subjects with eGFR <60 ml/min/1.73 m(2). Subjects in the highest quartiles within each eGFR category; >90, 60-90 and <60 ml/min/1.73 m(2) experienced HRs of 1.45 (95% CI 1.03-2.03), 1.35 (95% CI 1.00-1.83) and 1.72 (95% CI 1.14-2.58), respectively, compared with subjects in the lowest quartile group. The patterns were similar for cardiovascular mortality. CONCLUSIONS: Plasma fibrinogen associates with mortality among subjects with mild to moderate kidney impairment as it does in subjects with normal kidney function and should be considered a therapeutic target for cardiovascular risk reduction.
BACKGROUND: The contribution of novel risk factors to mortality in chronic kidney disease remains controversial. AIM: To explore the association of plasma fibrinogen with mortality among individuals with normal and reduced kidney function. METHODS: We identified 9184 subjects, age 40 and over from the Third National Health and Nutrition Examination Survey (1988-94) with vital status assessed through 2006. Plasma fibrinogen was modeled as continuous variable and in quartile groups (0 to <7.7, 7.7 to <9.0, 9.0 to <10.5 and ≥ 10.5 µmol/l) with total and cardiovascular mortality across categories of glomerular filtration rate (eGFR); <60, 60-90, >90 ml/min/1.73 m(2) using Cox regression. RESULTS: In multivariate analysis, the adjusted hazard ratio (HR) per 1 µmol/l (34 mg/dl) increase in fibrinogen was 1.07 [95% confidence interval (CI) 1.04-1.09] for total mortality and 1.06 (95% CI 1.03-1.09) for cardiovascular mortality. The adjusted HR for total mortality was 1.05 (1.01-1.09) for subjects with eGFR 60-90 ml/min/1.73 m(2) and 1.06 (1.02-1.10) for subjects with eGFR <60 ml/min/1.73 m(2). Subjects in the highest quartiles within each eGFR category; >90, 60-90 and <60 ml/min/1.73 m(2) experienced HRs of 1.45 (95% CI 1.03-2.03), 1.35 (95% CI 1.00-1.83) and 1.72 (95% CI 1.14-2.58), respectively, compared with subjects in the lowest quartile group. The patterns were similar for cardiovascular mortality. CONCLUSIONS: Plasma fibrinogen associates with mortality among subjects with mild to moderate kidney impairment as it does in subjects with normal kidney function and should be considered a therapeutic target for cardiovascular risk reduction.
Authors: Katharina Schuett; Anna Savvaidis; Sebastian Maxeiner; Katharina Lysaja; Vera Jankowski; Stephan H Schirmer; Nada Dimkovic; Peter Boor; Nadine Kaesler; Friedo W Dekker; Jürgen Floege; Nikolaus Marx; Georg Schlieper Journal: J Am Soc Nephrol Date: 2017-01-05 Impact factor: 10.121
Authors: Jennifer Straatman; Miguel A Cuesta; Elly S M de Lange-de Klerk; Donald L van der Peet Journal: J Gastrointest Surg Date: 2016-02-08 Impact factor: 3.452
Authors: Anna C Belkina; Alina Starchenko; Katherine A Drake; Elizabeth A Proctor; Riley M F Pihl; Alex Olson; Douglas A Lauffenburger; Nina Lin; Jennifer E Snyder-Cappione Journal: Front Immunol Date: 2018-12-05 Impact factor: 8.786
Authors: Łukasz Kuźma; Jolanta Małyszko; Hanna Bachórzewska-Gajewska; Marta Maria Niwińska; Anna Kurasz; Małgorzata Zalewska-Adamiec; Marcin Kożuch; Sławomir Dobrzycki Journal: Int Urol Nephrol Date: 2020-07-14 Impact factor: 2.370
Authors: Elshaeima Mohammed; Leonard D Browne; Arun Kumar A U; Fahd Adeeb; Alexander D Fraser; Austin G Stack Journal: PLoS One Date: 2019-01-25 Impact factor: 3.240